Fortress Biotech, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Intangible Assets

Intangible Assets

6 Months Ended

Jun. 30, 2025

7. Intangible Assets, net

The Company’s finite-lived intangible assets consist of intangible assets acquired by Journey. The table below provides a summary of the Journey intangible assets for the periods presented:


	Estimated Useful	June 30,		December 31,
($ in thousands)	Lives (Years)	2025		2024
Intangible assets – product licenses	3 to 15	$	52,925	$	52,925
Accumulated amortization			(20,048)		(17,919)
Accumulated Impairment loss			(3,143)		(3,143)
Net intangible assets		$	29,734	$	31,863

For the three months ended June 30, 2025 and 2024, Journey’s amortization expense related to its product licenses was $1.1 million and $0.8 million, respectively. For the six months ended June 30, 2025 and 2024, Journey’s amortization expense related to its product licenses was $2.1 million and $1.6 million, respectively.

The future amortization of these intangible assets is as follows:


	Total
For the years ended: ($ in thousands)	Amortization
Remainder of 2025	$	2,128
2026		3,471
2027		2,775
2028		2,595
2029		2,595
Thereafter		12,228
Sub-total	$	25,792
Asset not yet placed in service		3,942
Total	$	29,734